Research programme: antibacterials - ImaGeneAlternative Names: OX-22-043; OX-22-045; Oxazolidinone antibacterials research programme - ImaGene; PDF 10034; PDF 10035; Peptide deformylase inhibitors research programme - ImaGene
Latest Information Update: 01 May 2007
At a glance
- Originator ImaGene
- Mechanism of Action Peptide deformylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Gram-positive infections
Most Recent Events
- 27 Nov 2002 Preclinical trials in Gram-positive infections in South Korea (unspecified route)